Side-by-Side Comparison
Semaglutide vs Retatrutide: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how Semaglutide and Retatrutide differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Also: Ozempic, Wegovy, Rybelsus
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.
Also: LY3437943, Triple Agonist
A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.
Side-by-side comparison
| Attribute | Semaglutide | Retatrutide |
|---|---|---|
| Primary mechanism | GLP-1 Receptor Agonism | Triple GIP/GLP-1/Glucagon Agonism |
| FDA status | FDA Approved | In Clinical Trials |
| Evidence level | FDA Approved | Strong Clinical Evidence |
| Human trials | Yes (100+ indexed) | Yes (4+ indexed) |
| Studies indexed | 630 total (380 human, 120 animal) | 31 total (8 human, 12 animal) |
| Primary uses researched | Weight management, Type 2 diabetes, Cardiovascular risk reduction | Weight management, Type 2 diabetes, NASH/MASLD |
| Administration routes | oral, subcutaneous | subcutaneous |
| Molecular weight | 4113.58 Da | 4604.43 Da |
| Amino acids | 31 | 39 |
| Category | weight loss | weight loss |
| WADA status | Permitted | Permitted |
Key differences
Mechanism. Semaglutide acts primarily through glp-1 receptor agonism, while Retatrutide acts primarily through triple gip/glp-1/glucagon agonism. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. Semaglutide is classified as fda approved; Retatrutide is classified as in clinical trials. Regulatory status drives availability, legality, and the standard of evidence required for specific therapeutic claims.
Evidence base. Semaglutide sits at a higher evidence level (L5) than Retatrutide (L4) under PeptideMark's L1–L5 methodology, which weighs study type, sample size, and replication.
Research focus. Published research on Semaglutide has concentrated on weight management, type 2 diabetes, cardiovascular risk reduction. Research on Retatrutide has concentrated on weight management, type 2 diabetes, nash/masld. There is meaningful overlap between the two research programs, which is why these compounds are frequently compared.
Safety snapshot
| Attribute | Semaglutide | Retatrutide |
|---|---|---|
| Documented effects | 14 total | 9 total |
| Serious events | 1 | 1 |
| Common events | 5 | 5 |
| Black box warning | Yes | No |
| Contraindications | 3 listed | 3 listed |
| Drug interactions | 3 flagged | 2 flagged |
| Most common event | Nausea | Nausea |
Strengths & limitations
Semaglutide
Strengths
- FDA-approved with established regulatory record
- Strong evidence base (L5)
- Multiple human clinical trials (100+ indexed)
- Large indexed research base (630 studies)
Limitations
- Carries an FDA black box warning
Retatrutide
Strengths
- Strong evidence base (L4)
Limitations
- Direct head-to-head comparison data against peers is limited
Representative studies
Semaglutide
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Wilding JPH, Batterham RL, Calanna S, et al. · New England Journal of Medicine (2021)
Semaglutide 2.4mg weekly resulted in 14.9% mean body weight reduction, with 86.4% achieving ≥5% and 50.5% achieving ≥15% weight loss.
PubMed 33567185Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)
Garvey WT, Batterham RL, Bhatt DL, et al. · Nature Medicine (2022)
Semaglutide 2.4mg maintained 15.2% weight loss at 2 years, demonstrating durable efficacy with continued treatment.
PubMed 36356234Retatrutide
Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes
Rosenstock J, et al. · New England Journal of Medicine (2023)
Retatrutide 12mg produced mean weight loss of 24.2% at 48 weeks, the highest reported for any anti-obesity medication in trials.
PubMed 37351564TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)
Jastreboff AM, Aroda VR, Bray GA, et al. · Lancet Diabetes & Endocrinology (2024)
Retatrutide 15mg showed 25.3% weight loss vs 2.8% placebo (p<0.001), with 92% achieving ≥5% weight loss and 64% achieving ≥25% weight loss.
PubMed 38914872Frequently asked
What is the main difference between Semaglutide and Retatrutide?
Semaglutide is an fda-approved glp-1 receptor agonist used for type 2 diabetes and chronic weight management. Its primary mechanism is glp-1 receptor agonism. Retatrutide is a triple-acting gip/glp-1/glucagon receptor agonist in phase 3 trials showing potentially the highest weight loss of any drug in development. Its primary mechanism is triple gip/glp-1/glucagon agonism. The two differ in regulatory status (FDA Approved vs In Clinical Trials), strength of evidence (L5 vs L4), and the primary conditions for which each is researched.
Is Semaglutide or Retatrutide FDA approved?
Semaglutide: FDA-approved GLP-1 receptor agonist. Ozempic approved for type 2 diabetes (2017). Wegovy approved for chronic weight management (2021) and cardiovascular risk reduction (2024). Retatrutide: Currently in Phase 3 clinical trials. Not yet FDA-approved. Triple GIP/GLP-1/glucagon receptor agonist developed by Eli Lilly.
How does the evidence base compare?
Semaglutide has 630 indexed studies (380 human, 120 animal) and is rated FDA Approved. Retatrutide has 31 indexed studies (8 human, 12 animal) and is rated Strong Clinical Evidence. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can Semaglutide and Retatrutide be compared directly?
Yes — both compounds share the weight loss category, meaning head-to-head comparisons are meaningful for the same therapeutic targets. Direct head-to-head trials between peptides are rare, however, so most comparisons rely on separate trial datasets rather than direct RCT data.
Are Semaglutide and Retatrutide commonly stacked together?
There is no widely documented stacking protocol combining Semaglutide and Retatrutide in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, Semaglutide or Retatrutide?
Semaglutide has 14 documented side effects (1 serious, including a black box warning). Retatrutide has 9 documented side effects (1 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are Semaglutide and Retatrutide administered?
Semaglutide is typically administered via oral or subcutaneous. Retatrutide is typically administered via subcutaneous. Route differences affect onset, peak levels, and patient convenience.
Which is better, Semaglutide or Retatrutide?
"Better" depends on the therapeutic goal, regulatory context, and individual response. Semaglutide is most researched for weight management and type 2 diabetes; Retatrutide is most researched for weight management and type 2 diabetes. FDA status also matters: FDA Approved for Semaglutide vs In Clinical Trials for Retatrutide. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
Semaglutide →
Full profile
Retatrutide →